Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals is a biopharmaceutical company. The company discovers the functions and pharmaceutical utility of genes and uses those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease. The company is commercializing XERMELO? (telotristat ethyl), an orally-delivered small molecule drug for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. The company is also developing sotagliflozin as a treatment for type 1 and type 2 diabetes; LX9211 as a treatment for neuropathic pain; and LX2761 as a treatment for diabetes.
  • TickerLXRX
  • ISINUS5288723027
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for LXRX

ValuEngine Rating and Forecast Report for LXRX

ValuEngine Rating and Forecast Report for LXRX

ValuEngine Rating and Forecast Report for LXRX

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Kambiz Yazdi ...
  • Liana Moussatos
  • Shveta Dighe

Presentations at NANETS Highlight Real-World Benefit of XERMELO

2 directors bought

Two Directors at Lexicon Pharmaceuticals Inc bought 54,500 shares at between 3.100USD and 3.359USD. The significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under ...

ValuEngine Rating and Forecast Report for LXRX

ValuEngine Rating and Forecast Report for LXRX

ValuEngine Rating and Forecast Report for LXRX

ValuEngine Rating and Forecast Report for LXRX

ValuEngine Rating and Forecast Report for LXRX

ValuEngine Rating and Forecast Report for LXRX

ValuEngine Rating and Forecast Report for LXRX

ValuEngine Rating and Forecast Report for LXRX

ValuEngine Rating and Forecast Report for LXRX

ValuEngine Rating and Forecast Report for LXRX

ResearchPool Subscriptions

Get the most out of your insights

Get in touch